WireTensors
Remedy Robotics N1 logo

Remedy Robotics N1 review

3.4

An AI-enabled endovascular surgical system designed for autonomous or assisted minimally invasive vascular procedures.

Last verified 2026-11-17 — We did not find a pricing page at the addresses we tried (the site returned HTTP 404).

WireTensors rating

3.4/5

Time saved: No real clinical data on time per procedure or complication rates has been published; this is too early-stage to claim specific time savings..

Key facts

Remedy Robotics N1 key facts
Tool Remedy Robotics N1
Category Productivity
Pricing Pricing not publicly listed at time of review
Free tier No
WireTensors rating 3.4 / 5
Best for Large academic medical centres and specialised vascular surgery programs participating in clinical trials or early FDA-cleared deployment.
Avoid if You need a mature, proven technology with established safety data and commercial availability; most healthcare systems cannot yet access this product.
Affiliate commission Pending affiliate program review
Cookie window N/A
Last verified 2026-11-17

Insights for Remedy Robotics N1

Facts computed from our catalogue, refreshed daily (2026-11-19). How these are calculated.

Rating position
#94 of 194 productivity listings (rated 3.4/5; category median 3.4). Higher than 49% of the other listings in the category.
Alternatives
193 other listings in Productivity. Browse the category.
Free tier
No. 72.2% of productivity listings offer one.
Entry price
No numeric price on record for this listing, so it is not ranked on price. See the vendor's pricing page.
Price changes, last 30 days
None recorded.
Where it appears
0 best-of guides; 0 head-to-head comparisons.
Freshness
Review last verified 2026-11-17 (2 days ago). Vendor pricing page is not fetched automatically yet.
Visits and outbound clicks (last 11 days)
2 visits to this review and 1 clicks on its Visit links. Top countries (by visits): CN (1), FR (1).First-party counts since 2026-11-09; known bots and Do Not Track visitors excluded.

Overview

Remedy Robotics, a San Francisco-based surgical robotics company, raised $62 million in Series B funding in November 2026 to advance its N1 AI-enabled endovascular surgical system toward clinical deployment. Endovascular surgery involves navigating catheters and tools through blood vessels to treat conditions (aneurysms, stenosis, thrombosis) without large incisions; it demands exceptional manual dexterity and real-time spatial reasoning, making it a candidate for robotic assistance and AI guidance. The N1 system reportedly combines machine-learning-driven image analysis (likely from intraoperative angiography or ultrasound), real-time anatomical mapping, and autonomous or assisted tool control to improve procedural precision and safety. The company has secured partnerships with over 100 hospitals for trials and is pursuing FDA regulatory clearance; clinical trial data is not yet publicly available. This positions Remedy in an earlier stage than most established surgical robotics (Intuitive Surgical's da Vinci, Medtronic's Hugo), though the AI-autonomous aspects distinguish it from purely teleoperated systems. The endovascular space is less saturated than general surgery, and fatigue-related errors in long procedures represent a genuine clinical problem; however, the regulatory pathway is complex, and meaningful clinical superiority must be demonstrated against current minimally invasive standards. Pricing is unknown and will likely be premium until Medicare and insurance codes are established. Early adopters will be top-tier academic centres with research missions and budgets for breakthrough devices; deployment across community hospitals is likely 5+ years away. The fundamental risk remains unproven: does AI-assisted endovascular surgery actually improve outcomes, reduce complications, and justify its cost versus current practice?

Pros

  • First clinical-stage AI surgical system in its category with significant institutional backing (Series B: $62M)
  • Addresses critical unmet need in endovascular surgery where manual precision is demanding and surgeon fatigue is a factor
  • FDA pathway and 100+ hospital partnerships in trial phase demonstrate real institutional validation

Cons

  • Extremely early-stage clinically; long timeline to commercial deployment and regulatory clearance
  • No published data on safety outcomes, error rates, or clinical superiority versus human surgeons
  • Pricing and eventual market availability unknown; likely to remain expensive and inaccessible to most healthcare systems for years

Who it is for

Who this is for

Chief surgeons and interventional radiologists at leading academic medical centres with endovascular programmes. Senior hospital administrators responsible for surgical innovation and participating in breakthrough device trials. Medical device procurement teams at institutions invited into early access or trial cohorts.

Who should skip this

Community hospitals, rural healthcare systems, and practices outside trial networks have no access. Patients should be cautious of unvetted claims until peer-reviewed clinical results are published. Healthcare administrators seeking near-term ROI should focus on proven technologies; this is a multi-year, high-risk commitment.

Verdict

Remedy Robotics N1 represents genuine innovation in surgical automation with serious institutional backing and trial partnerships. However, it remains pre-commercial with no published clinical outcomes, making it unsuitable for immediate procurement. This is a watch-and-wait opportunity for research institutions; the broader market should revisit once peer-reviewed efficacy data are published and FDA clearance is achieved.

User reviews

Real reader reviews — separate from WireTensors' own editorial rating above. Every submission is moderated before it appears here.

Loading reviews…

Write a review

Remedy Robotics N1 FAQ

What is Remedy Robotics N1? +

Remedy Robotics, a San Francisco-based surgical robotics company, raised $62 million in Series B funding in November 2026 to advance its N1 AI-enabled endovascular surgical system toward clinical deployment. Endovascular surgery involves navigating catheters and tools through blood vessels to treat conditions (aneurysms, stenosis, thrombosis) without large incisions; it demands exceptional manual dexterity and real-time spatial reasoning, making it a candidate for robotic assistance and AI guidance. The N1 system reportedly combines machine-learning-driven image analysis (likely from intraoperative angiography or ultrasound), real-time anatomical mapping, and autonomous or assisted tool control to improve procedural precision and safety. The company has secured partnerships with over 100 hospitals for trials and is pursuing FDA regulatory clearance; clinical trial data is not yet publicly available. This positions Remedy in an earlier stage than most established surgical robotics (Intuitive Surgical's da Vinci, Medtronic's Hugo), though the AI-autonomous aspects distinguish it from purely teleoperated systems. The endovascular space is less saturated than general surgery, and fatigue-related errors in long procedures represent a genuine clinical problem; however, the regulatory pathway is complex, and meaningful clinical superiority must be demonstrated against current minimally invasive standards. Pricing is unknown and will likely be premium until Medicare and insurance codes are established. Early adopters will be top-tier academic centres with research missions and budgets for breakthrough devices; deployment across community hospitals is likely 5+ years away. The fundamental risk remains unproven: does AI-assisted endovascular surgery actually improve outcomes, reduce complications, and justify its cost versus current practice?

How much does Remedy Robotics N1 cost? +

Remedy Robotics N1 pricing: Pricing not publicly listed at time of review. Always confirm current pricing on the official site, as plans change.

Does Remedy Robotics N1 have a free tier? +

No. Remedy Robotics N1 does not offer an ongoing free plan, though a trial may be available.

What is Remedy Robotics N1 best for? +

Large academic medical centres and specialised vascular surgery programs participating in clinical trials or early FDA-cleared deployment..

When should you avoid Remedy Robotics N1? +

Avoid Remedy Robotics N1 if: You need a mature, proven technology with established safety data and commercial availability; most healthcare systems cannot yet access this product..

What are the main pros of Remedy Robotics N1? +

First clinical-stage AI surgical system in its category with significant institutional backing (Series B: $62M); Addresses critical unmet need in endovascular surgery where manual precision is demanding and surgeon fatigue is a factor; FDA pathway and 100+ hospital partnerships in trial phase demonstrate real institutional validation.

What are the main cons of Remedy Robotics N1? +

Extremely early-stage clinically; long timeline to commercial deployment and regulatory clearance; No published data on safety outcomes, error rates, or clinical superiority versus human surgeons; Pricing and eventual market availability unknown; likely to remain expensive and inaccessible to most healthcare systems for years.

Does Remedy Robotics N1 have an affiliate program? +

No public affiliate program is listed for Remedy Robotics N1 at the time of review.

How is Remedy Robotics N1 rated? +

WireTensors rates Remedy Robotics N1 3.4 out of 5, based on capability, value, and fit for its intended use case.

What category does Remedy Robotics N1 fall under? +

Remedy Robotics N1 is categorised under productivity on WireTensors.

When was this Remedy Robotics N1 review last verified? +

This review was last verified on 2026-11-17 against the vendor's official site.

Published by Binary Tech Stay Solutions

Researched and drafted with AI from official sources, then checked by automated tests. Pages are not individually reviewed by a named human editor.

How we make this

Last verified:

Sources